

آنچه همه باید درباره دخانیات بدانند



گردآوری:

دکتر غلامرضا حیدری

زیر نظر:

دکتر محمدرضا مسجدی



تعاونی اعتبارشامن (مکج ع)



ارمغان بهبود ایرانیان



:

:

:

:

.....

.....

.....

.....

.....

.....

.....

.....


.....

.....

.....

.....

.....






•
•
•

**National Archives and
Records
Administration**

Camel

Marlboro


	 <p data-bbox="948 1792 1264 1818">Borio G. Tobacco Timeline, 1998</p>
--	--

(Hill)


(Doll)

()

-
-
-
-



Borio G. Tobacco Timeline. 1998




Higher nicotine content

(tobac)

Domesticated plant

Y





:

(Smoking tobacco) (

(Cigarette)

(Hand rolled)

(Manufactured)

(Bidi)

(Kreteks)


:(Cigar)

(Smokeless tobacco) (

Loose leaf

Plug

Twist





()

(Tombac)

%

%




Altria / Philip Morris	64	
BAT	100	
JTI	81	
Imperial Tobacco Group	100	
Gallahar Group	100	
Altadis	77	

Source: Tobacco Atlas

		()	
Japan	14.9	US	28.4
France	10.8	Netherlands	14.9
Hong Kong	8.9	UK	9.5
Italy	7.0	Hong Kong	7.9
Singapore	5.2	Germany	7.2
Germany	4.4	Singapore	5.4
Russian Fed.	4.2	China	4.9
Iran	3.9	Switzerland	2.0
Netherlands	3.5	Belgium / Luxembourg	1.8
US	1.3	Canada	0.4

:



:

() JTI () BAT
· ()

BAT

BAT

BAT

BAT .

/

RJ Reynolds .

BAT

()

() ()

1- China National Tobacco corporation		>
2- Philip Morris		>
3- British American Tobacco (BAT)		>
4- Japan Tobacco		>
5- Tabakprom		<
6- Altadis	-	<
7- RJ Reynolds		<
8- KT & G		<
9- Tekel		<

10- Reemtsma		<
11- Gudang Garam		<
12- ITC		<
13- AAMS		<
14- Imperial Tobacco		<
15- Lorillard		<
16- TTM		<
17- Gallaher		<
18- Fortune Tobacco		<
19- HMS		<
20- Austria Tobacco		<
21- Taiwan Monopoly		<

Source: Goldman Sachs Global Equity Research

:


()


-

-


-


	:		
(ETS)	.	.	-
	.	()	-
	.		-
) FCTC	() WHO	-
		(-
	.		





)
) ((






(Environmental Tobacco Smoke)

ETS

ETS


).
(



BAT

USA

()



)

%

.(

)

.(

"

"

()

"

"

)

(


"

"

:

-

-



:

:

(Main stream)

(Side stream)

)

(

(

) Passive Smoking




%

()

:


% : (

% : (



:(CO)

:()





:(PH210)

(CXR)

● Polynuclear aromatic hydrocarbons (PAHs)	● Aldehydes
— benzoopyrene	● Organic compounds
● Aza-arenes	— 1,3-butadiene
● N-nitrosamines	— benzene
● Aromatic amines	— vinyl chloride
— 2-Napthylamine	— acrylamide
	● Inorganic compounds



Hoffmann and Hoffmann. 1997



-
-
-
-
-
-
-
-



Source: J Henningfield



:


()

— —


—

...

(COPD)



• • • • •
• () • • •
• • • • •



-
-
-
-
-
-
-
-

-
-

-
-


• • GoodPasture • • • COPD •

-
-

-
-
-
-

-
-
-

-
-
-
-



• •

• •


•

• (Prematurity) •

•


%

%

% / :	• • • • • •	
% / :		*Ries et al, 2000

—

—



LDL

O₂

()

:(COPD)


()

COPD


—

COPD

•
•
•




The diagram illustrates the human torso from the neck to the pelvis, showing internal organs and the circulatory system. The brain is visible at the top. The heart is centrally located, with blue vessels representing oxygenated blood and red vessels representing deoxygenated blood. The lungs are shown on either side of the heart. The stomach and intestines are visible in the abdominal cavity. The diagram is set against a dark blue background.



%


%

%



()


()



McGinnis and Foege, 1993

%

	/	
	/	
	/	



. « »

.

%

% (* = .)

.

%

.

%

%

.

%

%

%

%

%

%

%

%

:

:

:

«

»

:

:

/

:

%

%

%

% /

%

%

%

:

/

() .

%

%

Rothmans

BAT

:Green Tobacco Sickness

: %

/

/

/

:

/

)

(

/


).

/

(

%

/




»

«

•

•

•




/

Philip Morris, BAT, Japan Tobacco


•

•

•



%



%

—

—


()

%

Peto

)

(



(Stillbirth)


(SGA)

(SIDS)

(Neonatal death)

– (D coulement)

– (PROM)




(placenta previa)

%

(CI:%) /

(Confidence of Interval: %)



(CI:%) /

(OCP)

OCP

OCP

OCP

OCP

—

OCP

OCP

/

%

COPD

COPD


. /

FEV₁ COPD % . COPD
CPS II

(% %)

— — — —
%

).
% .(
%



/

/

(%)


(/)

Mormon

/)

(/) (

CPS II



/

/

% /

(

)

(


% /)

(

)

/

Peto



%

%


%

%

(%)

%

%



()
/) (


(%)

% % % /
% %

(% /)

% /

/ /



%

FEV₁

FEV₁


/

/

/

/

/




:

%


%

%

%



% /




COPD

()


/

/



WHO

WHO



:

:


(ETS)

Micro environment

ETS



Micro environment

Micro environment



Micro environment

(ETS)




ETS


:

:



COHB





Micro environment



Passive







% /

% /

% /

% /

%

% /

% /

% /

% /

% /

% /

% /

% /

% / % /

% /

% /


% /

% /

/	/	/	/		
/	/		/		
/ /	/	/ /	/ /	/	/
	/	/	/	/	
	/	/	/	/	
	/	/	/	/	

:

/



WARNING: CIGARETTES CAUSE LUNG CANCER

85% of lung cancers are caused by smoking. 80% of lung cancer victims die within 3 years.

Health Canada


Cigarettes

DON'T POISON US

WARNING: Second-hand smoke contains nicotine, carbon monoxide, ammonia, formaldehyde, benzo[a]pyrene and nitrosamines. These chemicals can harm your children.

Health Canada

Cigarettes



() () ():

: :

%

: :

()

(

(

: (

...

:

-
-
-

-

-

-

-

-

-

-

-

-

-

-

-


(.) .

:

:

-

:



«

» :

:

:


» «

»

«

•

•



•

:

•

...

•

«

»

•

•

•

•


•

•

•

•

•



:

:

•

:

•

:

•

:

:

:

:

•

•

•

•

•

•

•

)

(

« »

(MCI)

MCI

%

%

%

()

%

%

(MCI)

:

MCI


)

MCI

(

:

MCI



(

(

(

:

MCI

()

•



()

•

•

•

•



.

:

..... :
..... :

:

:

-
-

..... :
..... :

:

⋮

.

⋮

«

»

⋮

/

»

«

.

()

•

•

•

•

•

•

()

•

() .

»

«

:

:

:

:

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•


•

•

•

:

:



-
-
-
-
-

:

.
:

.
.
.

.
:

:

-

.

•

/


•

•

)
()

(

•




∴

-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

» «

»

«



•

() .

:


•

.

.

.

:



)


(

:

/

(NRT)

NRT




: NRT
()

.()

().

: •



)

:

•

.(

:


•

(

)

:


•




: •
: •

x
x
x


:





)

(



(%)

(ask) : A

(assess)

(advise)

(arrange)


(assist)

()

(OR=1.2)

(OR=1.4)

()




« »

()

()

% /

%



« »


) www.quitnet.org

) www.stop-tabac.ch (

(


www.netdoctor.com

.(% %)




%

WHO




%

%



() ICD-10



(NRT)

)


(

EEG

:

□

()



NRT

NRT

NRT


NRT

NRT

%

:NRT






NRT

()

()

%




NRT



%

%



%

%

%

NRT



(%)

(%)

(%)



/

ul

()

mg/ml

□


($P < 0.01$ % %) .

)

% % % % (

%

%



)

NRT

(


(

)

NRT

NRT

NRT



NRT


) :

(:

%

NRT :

□



USA


()

()

FDA

/

OR





B

/

OR

()





%

()

()

%

()


%

%


()

(
(
(
(

().



(a)



)

(

Panel

:

:


)

(

(

=

)



((:

(

(5A's)

(A₂)

(A₁)

)

(A₃)

(A₅)

(A₄

()

NCI ()

()

(A ₁)	
(A ₂)	
(A ₃)	
(A ₄).	
(A ₅)	

FDA SR bupropion, nicotin patch, nicotin nasal nicotin spray, nicotin inhaler, nicotin gum	
) () (

bupropion	
Nortriptyline, Clonidine	
() bupropion FDA) (

- Assess . A₃

<p>:</p> <p>(A₄)</p> <p>().</p> <p>().</p> <p>)</p> <p>(</p> <p>()</p>	<p>)</p> <p>(</p>

- Assist .A₄

) (
)". (
" "	
). (()
SR bupropion, : nicotine patch, nicotine nasal spray, nicotine	

inhaler, nicotine gum	
A) (/ / /	


Arrange .A₅

()	

:

<p>)</p> <p>(</p> <p>:</p> <p>CO</p> <p>:</p> <p>()</p> <p>()</p> <p>:</p> <p>SIDS</p> <p>.</p>	<p>Risks</p>
<p>.</p> <p>:</p>	<p>Rewards</p>

(:)	Road blocks
	Repetition




(C₁)

Assist . A₄)

(5R's .B

)

(



:

(C₂)

() .

.

:

.C₁

.

.

()

:

()

)

.

.

.

.(

C₂

:	
bupropion) (NRTs	
()	

REFERENCES:

1. American Psychiatric Association (1996). Practice guideline for the treatment of patients with nicotine dependence. *The American Journal of Psychiatry*, 153,1-31.
2. Benowitz NL (1993). Nicotine replacement therapy-What has been accomplished-Can we do better? *Drugs*, 45:157-170.
3. Benowitz NL (1995). Clinical pharmacology of transdermal nicotine. *European Journal of Pharmaceutics and Biopharmaceutics*, 41:168-174.
4. Benowitz NL (1998). Summary: Risks and benefits of nicotine. In: *Nicotine Safety and Toxicity* (Benowitz NL ed) pp 185-194, Oxford University Press, New York.
5. Benowitz NL and Gourlay SG (1997). Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. *Journal of the American College of Cardiology*, 29:1422-1431.
6. Benowitz NL, Jacob III P, and Sannerstrom C (1987). Determinants of nicotine intake while chewing nicotine polacrilex gum. *Clinical pharmacology and Therapeutics*, 41:467-473.
7. Bohadana A, Nilsson F, Rasmussen T, and Martinet Y (2000). Nicotine inhaler and nicotine patch as a combination therapy for smoking cessation: a randomized, double-blind, placebo-controlled trial. *Archives of Internal Medicine*, 160:3128-3134.

-
-
8. Borland R, Owens N, Hocking B (1991). Changes in smoking behaviour after a total workplace smoking ban. *Australian Journal of Public Health*. 1991; 15(2):130-134.
 9. Cavalcante T. Smoking cessation experience in Brazil. Presentation at the occasion of the WHO meeting on Global Policy for Smoking Cessation hosted by the Ministry of Health of the Russian Federation, Moscow, 14-15 June 2002.
 10. Choi, J., Dresler, C. M., Norton, M. R., and Strahs, K. R (in press). Pharmacokinetics of a nicotine polacrilex lozenge. *Nicotine and Tobacco Research*.
 11. Crone S. Quit lines and internet-based services. Presentation at the occasion of the WHO meeting on Global policy for Smoking Cessation hosted by the Ministry of Health of the Russian Federation, Moscow, 14-15 June 2002.
 12. Dempsey DA and Benowitz NL (2001). Risks and benefits of nicotine to aid smoking cessation in pregnancy. *Drug Safety*, 24:277-322.
 13. Emont SL, Choi WS, Novotny TE, Giovino GA. (1993). Clean indoor air legislation, taxation and smoking behaviour in the United States: an ecological analysis. *Tobacco Control*, 1993; 2(1):13-17.
 14. Etter, J. F. and T. V. Perneger (2001). A comparison of cigarette smokers recruited through the Internet or by mail. *International Journal of Epidemiology* 30(3): 521-525. Frant RV, Henningfield, JE, Shiffman S, Strahs KR, and Reitberg DP (2000). A pharmacokinetic crossover study to compare the absorption characteristics of three transdermal nicotine patches. *Pharmacology, Biochemistry and Behaviour*, 67;479-482.

-
-
15. Fiore MC, Bailey WC, Cohen SJ, et al (2000). Treating Tobacco Use and Dependence. Clinical Practice Guideline. Rockville, MD: US Department of Health and Human Services. Public Health Service.
 16. Fredrickson PA, Hurt RD, Lee GM, Wingender L, Croghan IT, Lauger G, Gomez-Dahl L, and Offord KP (1995). High dose transdermal nicotine therapy for heavy smokers: Safety, tolerability and measurement of nicotine and cotinine levels. *Psychopharmacology (Berl)*, 122:727-38.
 17. Gilpin EA, Stillman FA, Hartman AM, Gilbson JT, Pierce JP. (2000). Index for US state tobacco control initial outcomes. *American Journal of Epidemiology*, 2000; 152:727-38.
 18. Gorsline J (1993). Nicotine pharmacokinetics of four nicotine transdermal systems. *Health Values*, 17(2): 20-24.
 19. Gossop M (1988). Clonidine and the treatment of the opiate withdrawal syndrome. *Drug and Alcohol Dependence*, 21:253-259.
 20. Hajek P, Stead LF (2000). Aversive smoking for smoking cessation. In: *Cochran Collaboration*. Cochran Library. Issue 2. Oxford: Update Software.
 21. Jajek P, West RJ, Foulds J, Nilsson F, Burrows S, and Meadow A (1999). Randomized comparative trial of nicotine polacrilex, a tansdermal patch, nasal spray, and an inhaler, *Archives of Internal Medicine*, 159:2033-2038.
 22. Henningfield JE. Pharmacotherapy and behavioral therapy. Presentation at the occasion of the WHO meeting on Global Policy for Smoking Cessation hosted by the Ministry of Health of the Russian Federation, Moscow, 14-15 June 2002.

-
-
23. Henningfield JE, Slade J (1998). Tobacco-dependence medications: public health and regulatory issues. *Food Drug and Law Journal*, 53, suppl: 75-114.
 24. Henningfield JE, Fant RV, and Gopalan L (1998). Non-nicotine medications for smoking cessation. *The Journal of Respiratory Diseases*, 19:S33-S42.
 25. Henningfield JE (1995). Nicotine medications for smoking cessation. *New England Journal of Medicine*, 333:1196-1203.
 26. Heronimus J. Impact of workplace restrictions on consumption and incidence (memo to Louis Suwarna). Philip Morris: January 21, 1992: Access date, October 27, 2001. Bates Range 2045447779/7806 URL
 27. <http://www.pmdocs.com/getting.asp/pgno=>
 28. Hoffmann D and Hoffmann I (1997). The changing cigarette, 1950-1995. *Journal of Toxicology and Environmental Health*, 50:307-364.
 29. Hughes JR, Lesmes GR, Hatsukami Dk, Richmond RL, Lichtenstein E, Jorenby DE, Broughton JO, Fortmann SP, Leischow SJ, McKenna JP, Rennard SI, Wadland WC, and Heatley SA (1999). Are higher doses of nicotine replacement more effective for smoking cessation. *Nicotine & Tobacco Research*, 1:169-174.
 30. Hurt RD, Sachs DP, Glover ED, Offord KP, Johnston JA, Dale LC, Khayrallah MA, Schroeder DR, Glover PN, Sullivan CR, Croghan IT, and Sullivan PM (1997). A comparison of sustained-release bupropion and placebo for smoking cessation. *New England Journal of Medicine*, 337:1195-1202.

-
-
31. Jackson G, Bobak A, Chorlton I, Fowler G, Hall R, Khimji H, Matthews H, Stapleton J, Steele C, Stillman P, Sutherland G, Swanton RH (2001). Smoking cessation: a consensus statement with special reference to primary care. *Int.J.Clin. Pract*, 55:385-392.
 32. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, Smith SS, Muramoto ML, Daughton DM, Doan K, Fiore MC, and Baker TB (1999). A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. *New England Journal of Medicine*, 340:685-691.
 33. Jorenby DE, Smith SS, Fiore MC, Hurt RD, Offord KP, Croghan IT, Hays JT, Lewis SF, and Baker Tb (1995). Varying nicotine patch dose and type of smoking cessation counseling. *The Journal of the American Medical Association*, 274:1347-1352.
 34. Kornitzer M, Boutsen M, Dramaix M, Thijs J, and Gustavsson G (1995). Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled clinical trial. *Preventive Medicine*, 24:41-47.
 35. Lam TH. Smoking cessation experience in Hong Kong. Presentation at the occasion of the WHO meeting on Global policy for Smoking Cessation hosted by the Ministry of Health of the Russian Federation, Moscow, 14-15 June 2002.
 36. Lunell E, Bergstrom M, Antoni G, Langstrom B, Nordberg A (1996). Nicotine deposition and body distribution from a nicotine inhaler and a cigarette studied with positron emission

-
-
- tomography. *Clinical Pharmacology and Therapeutics*, 59:593-594.
37. McClain H and Sapeinza F (1989) The role of abuse liability testing in drug control procedures. In: Fischman MW and Mello NK, eds, *Testing for Abuse Liability of Drugs in Humans* () pp 21-42, US Department of Health and Human Services, Rockville, MD.
 38. Molander L and Lunell E (2001). Pharmacokinetic investigation of a nicotine sublingual tablet. *European Journal of Clinical Pharmacology*, 56:813-819.
 39. Molander L, Lunell E, Andersson SB, Kuylentierna F (1996). Dose released and absolute bioavailability of nicotine from a nicotine vapor inhaler. *Clinical Pharmacology and Therapeutics* 59:394-400.
 40. National Cancer Institute. (1991). *Strategies To Control Tobacco Use in the United States: A Blueprint for Public Health Action in the 1990s*. Smoking and Tobacco Control Monographs-1. Bethesda, Maryland: United States Department of Health and Human Services, National Institutes of Health, National Cancer Institute, NIH Publication No. 92-3316, October 1991.
 41. Oncken CA (1996). Nicotine replacement therapy during pregnancy. *American Journal of Health Behavior*, 20:300-303.
 42. Owen L. Impact of a Telephon Helpline for Smokers who Called During a Mass Media Campaign. *Tobacco Control*, (2000).9:148-154, London-United Kingdom.
 43. Prochaska JO, DiClemente CC, Velicer WF, Rossi JS (1993). Standardized, individualized, interactive, and personalized self-

-
-
- help programs for smoking cessation. *Health Psychology*, 12:399-405.
44. Puska P, Korhonen H, Vartiainen E, Urjanjeimo E, Gustavsson G, and Westin A (1995). Combined use of nicotine patch and gum compared with gum alone in smoking cessation: a clinical trial in North Karelia. *Tobacco Control* 4:231-235.
 45. Royal College of Physicians (2000). Nicotine Addiction in Britain. Royal College of Physicians of London, London, United Kingdom.
 46. Russell MAH, Merriman R, Stapleton J, and Taylor W (1983). Effect of nicotine chewing gum as an adjunct to general practitioner's advice against smoking. *British Medical Journal* 10:1782-1785.
 47. Sandstrom P. Quit and Win. Presentation at the occasion of the WHO meeting on Global Policy for Smoking Cessation hosted by the Ministry of Health of the Russian Federation, Moscow, 14-15 June 2002.
 48. Shiffman S, Elash CA, Paton SM, Gwaltney CJ, Paty JA, Clark DB, Liu KS, and Di Marino ME (2000). Comparative efficacy of 24-hour and 16-hour transdermal nicotine patches for relief of morning craving. *Addiction* 95:1185-1195.
 49. Smoking Cessation Guidelines, (2000). Thorax.
 50. South Asian Social Researcher's Forum (2001). An Evaluation of the Services of Asian Quitline.
 51. Stead LF, Lancaster T (2000). Group behaviour therapy programmes for smoking cessation. In: *Cochran Collaboration*. Cochran Library. Issue 3. Oxford: Update Software.

-
-
52. Stephens T, et al. (2001). Comprehensive tobacco control policies and the smoking behaviour of Canadian Adults. *Tobacco Control*, 2001;10:317-322.
 53. Stillman FA, Becker DM, Swank RT, Hantula D, Moses H, Glantz S, Waranch HR, (1990). Ending smoking at the Johns Hopkins Hospital: an evaluation of smoking prevalence and indoor air pollution. *Journal of the American Medical Association*, 264 (12):1565-1569.
 54. Sweeney CT, Fant RV, Fagerstrom KO, McGovern JF, and Henningfield JE (2001). Combination nicotine replacement therapy for smoking cessation: rationale, efficacy and tolerability. *CNS Drugs* 15:423-467.
 55. Takahashi, Y., K. Satomura, et al. (1999). "A new smoking cessation programme using the Internet." *Tobacco control*,
 56. Tonnesen P, Fryd V, Hansen M, Helsted J, Gunnensen AB, Forchammer H, and Stockner M (1988). Two and four mg nicotine chewing gum and group counseling in smoking cessation: an open, randomized, controlled trial with a 22 month follow-up. *Addictive Behaviors*, 13:17-27.
 57. Townsend J (2002). Monitoring and analyzing changes in Tobacco prices. In *Tobacco and Health* pp. 229-233, Plenum Press, New York.
 58. Transdermal Nicotine Study Group (1991). Transdermal nicotine for smoking cessation. *Journal of the American Medical Association*, 266:3133-3138.
 59. United States Food and Drug Administration (1996). Regulations restricting the sale and distribution of cigarettes

-
-
- and smokeless tobacco to protect children and adolescents; final rule. Federal Register 61:44369-45318.
60. United States Department of Health and Human Services (2000a). *Treating Tobacco Use and Dependence*.
61. United States Department of Health and Human Services (2000b). Reducing Tobacco Use. *A Report of the Surgeon General*. Atlanta, Georgia: United States Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health.
62. United States Department of Health and Human Services (2000c). Management of Nicotine Addiction. Reducing Tobacco Use: *A Report of the Surgeon General*. Washington, DC. United States Government Printing Office.
63. United States Department of Health and Human Services (1988). The Health Consequences Of Smoking, US Department of Health and Human Services, Washington, DC.
64. United States Food and Drug Administration (1995). Regulations restricting the sale and distribution of cigarettes and smokeless tobacco products to protect children and adolescents; proposed rule analysis regarding FDA's jurisdiction over nicotine-containing cigarettes and smokeless tobacco products; notice. Federal Register 60:41314-41792.
65. Wakefield M, Wilson D, Owen N, Esterman A, Roberts L (1992). Workplace smoking restrictions, occupational status and reduced cigarette consumption. *Journal of Occupational Medicine*, 1992;34(7):693-697.

-
-
66. Wallstrom M, Nilsson F, and Hirsch JM (2000) A randomized, double-blind, placebo-controlled clinical evaluation of a nicotine sublingual tablet in smoking cessation. *Addiction* 95:1161-1171.
67. West R. and Hine A. (2001). Internet-based stop smoking support: a survey of accessibility and demand. St George's Medical School, London, United Kingdom.
68. WHO Europe, www.treatobacco.net.
69. Wilson E. Smoking cessation experience in Canada. Presentation at the occasion of the WHO meeting on Global policy for Smoking Cessation hosted by the Ministry of Health of the Russian Federation, Moscow, 14-15 June 2002.
70. Windsor R, Oncken C, Henningfield J, Hartmann K, and Edwards N (2000). Behavioral and pharmacological treatment methods for pregnant smokers: issues for clinical practice. *Journal of the American Medical Women's Association*, 55:304-310.
71. World Bank (1999). *Curbing the Epidemic: Governments and the Economics of Tobacco Control*. The International Bank for Reconstruction and Development. The World Bank, Washington, DC.
72. World Health Organization (1992). *The ICD-10 Classification of Mental and Behavioural Disorders*. World Health Organization, Geneva.
73. Yuasa, H., et al. (2000). Investigation for smoking cessation support on Internet. Internet survey of Health and smoking awareness of users. *Nippon Koshu Eisei Zasshi* 47 (9): 820-827.